GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) have transformed weight management. The clinical results are unprecedented, with patients achieving 15 to 21% total body weight reduction in landmark trials. But as these medications become the standard of care for obesity, an important question is emerging from ...
Orthopedic surgery &
Sports Medicine Articles & Updates
